Cue Biopharma (CUE) EBIAT (2017 - 2025)
Cue Biopharma's EBIAT history spans 9 years, with the latest figure at -$7.4 million for Q3 2025.
- For Q3 2025, EBIAT rose 14.0% year-over-year to -$7.4 million; the TTM value through Sep 2025 reached -$37.7 million, up 15.53%, while the annual FY2024 figure was -$40.7 million, 19.83% up from the prior year.
- EBIAT for Q3 2025 was -$7.4 million at Cue Biopharma, up from -$8.5 million in the prior quarter.
- Across five years, EBIAT topped out at -$7.4 million in Q3 2025 and bottomed at -$14.6 million in Q4 2022.
- The 5-year median for EBIAT is -$12.3 million (2025), against an average of -$11.4 million.
- The largest annual shift saw EBIAT crashed 74.04% in 2022 before it increased 29.31% in 2024.
- A 5-year view of EBIAT shows it stood at -$8.4 million in 2021, then plummeted by 74.04% to -$14.6 million in 2022, then rose by 7.94% to -$13.4 million in 2023, then rose by 29.31% to -$9.5 million in 2024, then increased by 21.57% to -$7.4 million in 2025.
- Per Business Quant, the three most recent readings for CUE's EBIAT are -$7.4 million (Q3 2025), -$8.5 million (Q2 2025), and -$12.3 million (Q1 2025).